TRACON Announces Submission of Request for Type B Meeting with FDA to Discuss Trial Design for ENVASARC: A Potential Pivotal Study of Envafolimab in Sarcoma
TRACON Pharmaceuticals, Inc. (TCON)
Last tracon pharmaceuticals, inc. earnings: 2/27 04:03 pm
Check Earnings Report
US:NASDAQ Investor Relations:
traconpharma.com
Company Research
Source: GlobeNewswire
SAN DIEGO, March 16, 2020 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer and utilizing a product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the U.S., announced today that it has submitted a request for a Type B meeting with the U.S. Food and Drug Administration (FDA) to discuss the trial design for a potential pivotal study of envafolimab in sarcoma (ENVASARC). TRACON plans to propose a pivotal trial with two cohorts of approximately 80 patients each to assess the objective response rate in sarcoma subtypes known to be responsive to checkpoint inhibition, with one cohort receiving single-agent envafolimab and the second cohort receiving envafolimab and Yervoy (ipilimumab). “We have taken the first step towards beginning the ENVASARC study of envafolimab in sarcoma subtypes kn
Show less
Read more
Impact Snapshot
Event Time:
TCON
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TCON alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TCON alerts
High impacting TRACON Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
TCON
News
- TRACON Pharmaceuticals, Inc. (NASDAQ: TCON) was downgraded by analysts at StockNews.com from a "strong-buy" rating to a "buy" rating.MarketBeat
- TRACON to Report First Quarter 2024 Financial Results and Provide Corporate Update on May 14, 2024GlobeNewswire
- TRACON Pharmaceuticals, Inc. (NASDAQ: TCON) is now covered by analysts at StockNews.com. They set a "strong-buy" rating on the stock.MarketBeat
- TRACON Pharmaceuticals Announces Reverse Stock SplitGlobeNewswire
- TRACON Pharmaceuticals, Inc. (NASDAQ: TCON) is now covered by analysts at StockNews.com. They set a "strong-buy" rating on the stock.MarketBeat
TCON
Earnings
- 3/5/24 - Beat
TCON
Sec Filings
- 5/13/24 - Form 8-K
- 4/12/24 - Form S-1
- 4/12/24 - Form 8-K
- TCON's page on the SEC website